Open AccessEnucleation for gastrointestinal stromal tumors at the esophagogastric junction: Is this an adequate solution?
Author(s) -
Nadia Peparini,
Giovanni Carbotta,
Piero Chirletti
Publication year - 2011
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v17.i16.2159
Subject(s) - enucleation , gist , esophagogastric junction , medicine , stromal cell , esophagus , surgery , stomach , resection , oncology , gastroenterology , cancer , adenocarcinoma
The authors discussed the proposal by Coccolini and colleagues to treat gastrointestinal stromal tumors (GISTs) at the esophagogastric junction with enucleation and, if indicated, adjuvant therapy, reducing the risks related to esophageal and gastroesophageal resection. They concluded that, because the prognostic impact of a T1 high-mitotic rate on esophageal GIST is worse than that of a T1 high-mitotic rate on gastric GIST, enucleation may not be an adequate surgery for esophagogastric GISTs with a high mitotic rate in which the guarantee of negative resection margins and adjuvant therapies can be the only chance of survival.